Showing results (1101-1110 of 1,193) with videos related to

Sort By:
Pageof 120
Blood|December 7, 2016
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Kathryn G Roberts, Elias Jabbour, et al.
Kidney International Supplements|March 10, 2020
Considerations on equity in management of end-stage kidney disease in low- and middle-income countriesWim Van Biesen, Vivekanand Jha, Ali K Abu-Alfa, et al.
Cancer|March 19, 2021
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemiaElias Jabbour, Koji Sasaki, Nicholas J Short, et al.
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
Blood Cancer Discovery|August 4, 2022
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed SideroblastsVera Adema, Feiyang Ma, Rashmi Kanagal-Shamanna, et al.
Leukemia Research|July 12, 2025
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndromeJames M Foran, Guillermo F Sanz, Justin M Watts, et al.
Leukemia & Lymphoma|May 10, 2018
MYC protein expression is an important prognostic factor in acute myeloid leukemiaMaro Ohanian, Uri Rozovski, Rashmi Kanagal-Shamanna, et al.
Nature Communications|October 22, 2020
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Pageof 120